InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: None

Monday, 06/07/2010 9:58:11 PM

Monday, June 07, 2010 9:58:11 PM

Post# of 63
With the Levacor VAD Bridge-to-Transplant (BTT) clinical study underway, it's nice to see the company generating revenue. Based on the $556k booked in just the 1Q, it looks like their recovering around $185k per patient.

Currently the company has 3 medical centers participating but plans to bring on an additional 7 by the end of the summer which should result in more implants and greater revenue.